|
Dr. Stella Sung brings over a decade of experience in the healthcare sector. Prior to joining Cylene Pharmaceuticals, she was a Managing Director at Coastview Capital, a life science venture firm founded by Gordon Binder, Amgen’s CEO from 1988-2000. While at Coastview Capital, Dr. Sung served as the lead investor for the oversubscribed Series B round of financing for Cylene Pharmaceuticals. As an active investor and member of Cylene’s Board of Directors, Dr. Sung worked very closely with the Cylene management team before being recruited as Chief Business Officer. Dr. Sung has extensive experience in financing biotechnology companies. She has ten years of direct experience in life science venture capital and has led venture rounds of financing for seven transactions, co-founded two biotechnology companies, served on seven Boards of Directors and served as Chairman of the Board for four biotechnology companies. Prior to Coastview Capital, Dr. Sung was a General Partner at Oxford Bioscience Partners. Previously, she focused on life science and health care investments at Advent International, a global private equity firm that has raised over $6 billion in cumulative capital to date. Dr. Sung received her B.S. in chemistry from The Ohio State University and her Ph.D. in chemistry from Harvard University, where she was a National Science Foundation Pre-Doctoral Fellow. | 